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Abstract  
Objectives. To estimate the risk of diabetic nephropathy (DN) progression, incident coronary 
heart disease (CHD) and stroke, and all-cause mortality associated with resistant hypertension 
(RH) in individuals with type 1 diabetes stratified by stages of DN, renal function and sex.  
 
Research Design and Methods This prospective study included a nationally representative 
cohort of individuals with type 1 diabetes from the Finnish Diabetic Nephropathy Study who 
had purchases of antihypertensive drugs at (±6 months) baseline visit (1995–2008). Individuals 
(N=1,103) were divided into three groups: (a) RH, (b) uncontrolled BP, but no RH and (c) 
controlled BP. DN progression, cardiovascular events and deaths were identified from the 
individuals’ healthcare records and national registries, until 31 December 2015. 
 
Results At baseline 18.7% of the participants had RH, while 23.4% had controlled BP. After 
full adjustments for clinical confounders, RH was associated with increased risk of DN 
progression (HR 1.95 [95% CI 1.37, 2.79], p=0.0002), while no differences were observed in 
those with no RH (1.05 [0.76, 1.44], p=0.8), compared with those who had controlled BP. The 
risk of incident CHD, incident stroke and all-cause mortality was higher in individuals with 
RH compared with those who had controlled BP, but not beyond albuminuria and reduced 
kidney function. Notably, in those with normo- and microalbuminuria the risk of stroke 
remained higher in the RH compared to controlled BP group (3.49 [1.20, 10.15], p=0.02). 
Conclusion Our findings highlight importance to identify and provide diagnostic and 
therapeutic counseling to these very high risk individuals with RH. 
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Hypertension is a major risk factor for micro- and macrovascular complications in individuals 
with type 1 diabetes (1, 2). We recently reported that a large number of the antihypertensive 
drug-treated individuals with type 1 diabetes failed to reach the recommended blood pressure 
(BP) targets that may partly be explained by poor adherence to treatment and suboptimal 
antihypertensive drug regimen (3). Some of these individuals have a treatment-resistant 
hypertension (4). Resistant hypertension is defined as a BP above the treatment target if using 
a minimum of three or more antihypertensive drugs at optimal doses, of which one is a diuretic. 
Also, individuals with controlled BP using four or more antihypertensive drugs are considered 
resistant to treatment (5). Even though the definition is arbitrary with respect to the number of 
medications required, it may assist health care professionals to identify individuals at risk who 
may benefit from special diagnostic and therapeutic interventions (5). 
 
Notably, the prevalence of resistant hypertension is slightly higher in individuals with type 1 
diabetes than in the general hypertensive population. In the nationwide Finnish Diabetic 
Nephropathy Study (FinnDiane) cohort the prevalence of resistant hypertension was 17.0% 
(BP target <140/90 mmHg), while pooled data from Europe and North America estimated that 
14.8% of treated hypertensive individuals have resistant hypertension (3, 6). Similarly, a study 
from Italy indicated that about 14.9% of the treated individuals with type 2 diabetes have 
resistant hypertension (7). However, the true prevalence of resistant hypertension is unknown 
as these population-based studies were unable to exclude the cases with pseudo-resistance (i.e. 
white-coat hypertension, non-adherence to medication, suboptimal drug regimen) (5). 
Therefore, the term apparent treatment-resistant hypertension (RH) is more precise and widely 
used in population-based studies (5, 8, 9).  
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A few observational studies have demonstrated that RH is independently associated with an 
increased risk of all-cause mortality, and adverse cardiovascular and renal outcomes compared 
to those with controlled BP or non-RH in the general hypertensive population (10-14). These 
studies, however, varied by definitions of resistant and non-resistant hypertension and follow-
up times. Although the association between RH and diabetes has frequently been reported (15, 
16), longitudinal studies on the risk of adverse outcomes related to RH in the diabetes 
population are rare. Only one study has reported an association between RH and all-cause 
mortality in individuals with type 2 diabetes (7). In contrast to the general hypertensive 
population that study found that once indices of target organ damage were considered, RH did 
not predict death among individuals with type 2 diabetes. However, to date no studies have 
estimated the long-term risk of adverse outcomes associated with RH in a type 1 diabetes 
population. 
 
It is well known that chronic kidney disease (CKD) is among the most frequent secondary 
causes of RH and associated with worse outcomes (5). We previously showed that RH 
increases with albuminuria and reduced renal function in individuals with type 1 diabetes (3). 
Recently, colleagues from Italy reported that among individuals with type 2 diabetes and severe 
diabetic kidney disease, the presence of RH was associated with worse renal outcomes (17). 
While the associations between hypertension, cardiovascular events (1, 18, 19) and diabetic 
nephropathy (DN) (20) are well established in type 1 diabetes, data are scarce on the long-term 
prognosis and potential associations with severe outcomes in the individuals with RH. 
Therefore, we estimated the risk of DN progression, incident coronary heart disease (CHD) 
and stroke, as well as all-cause mortality, associated with RH in a nationally representative 
cohort of individuals with type 1 diabetes.  
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Research Design and Methods 
 
The present study is part of the ongoing, nationwide, multicenter FinnDiane study with the 
main aim of identifying genetic, clinical and environmental risk factors for diabetic 
complications in individuals with type 1 diabetes. A more detailed description of the study has 
been reported elsewhere (21, 22). Briefly, all individuals with type 1 diabetes from >80 
hospitals and health centers across Finland were asked to participate (Supplemental [Suppl.] 
Table S8, a list of the FinnDiane Study centers). Type 1 diabetes was defined by age at onset 
of diabetes <40 years, C-peptide ≤0.3 nmol/l and insulin treatment initiated within 1 year of 
diagnosis. Written informed consent was obtained from each patient. The study protocol was 
approved by the Ethics Committee of the Helsinki and Uusimaa Health District. The study was 
carried out in accordance with the Declaration of Helsinki. 
 
At baseline, all participants underwent a clinical examination, including blood and urine 
sampling. Details of the clinical characteristics of the individuals were obtained from medical 
records by the attending physician using a standardised questionnaire. Each participant also 
completed a detailed questionnaire on life style, smoking habits and family history. The 
measurement of height, weight, and waist and hip circumferences was performed in light 
clothing. At the baseline visit BP was measured twice with 2-min intervals in the sitting 
position after a 10-min rest using a mercury sphygmomanometer or an automated standardized 
BP device. The mean of these two measurements was calculated. Early morning blood samples 
were drawn and analysed for HbA1C, serum creatinine and lipids. The DN status was defined 
on the basis of the albumin excretion rate (AER) in at least two out of three overnight or 24h 
urine collections. Normal AER was defined as AER <20 µg/min or <30 mg/24h; 
microalbuminuria as AER ≥20<200 µg/min or ≥30<300 mg/24h; and macroalbuminuria as 
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AER ≥200µg/min or ≥300 mg/24h.  Individuals, who had end-stage renal disease (ESRD) at 
baseline, were excluded. At baseline, individuals were further classified into two DN status 
groups: those with normal AER or microalbuminuria and those with macroalbuminuria. The 
eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) formula (23). Similarly for further analyses, the individuals were divided into two renal 
function groups: eGFR ≥60 ml/min/1.73 m2 and eGFR <60 ml/min/1.73 m2. As a measure of 
insulin sensitivity, we used an equation for the estimated Rd (24). 
 
DN status and progression to a higher level of albuminuria or ESRD were derived from the 
individuals’ health care records and multiple national registries until the end of year 2015. 
Follow-up data on cardiovascular events (i.e. CHD and stroke) were identified by 31 December 
2015 from the Finnish Care Register of Health Care, which is the national hospital discharge 
register in Finland. The CHD events included the first acute myocardial infarction (ICD-8/9: 
410–412, ICD-10: I21–I23; and coronary procedure (bypass grafting surgery or angioplasty 
based on the Nordic Classifications of Surgical Procedures). The stroke included the first 
cerebrovascular accident (ICD-8/9: 430–434, ICD-10: I60–I64). All deaths, including fatal 
cardiovascular events, were identified from the Cause of Death Register until 31 December 
2015. 
 
Information on purchases of antihypertensive drugs 6 months before and after the baseline visit 
were obtained from the Finnish Drug Prescription Register (maintained by the National Social 
Insurance Institution since 1994 containing information on all prescribed, purchased and 
reimbursed medications in outpatient care). Medications were coded according to the Anatomic 
Therapeutic Chemical (ATC) classification, based on the 2019 ATC Index Version. 
Antihypertensive drugs were divided into eight classes: angiotensin-converting-enzyme (ACE) 
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inhibitors (ATC C09A, C09B), angiotensin II antagonists (C09C, C09D), diuretics (C03, 
C07BB, C09BA, C09DA), β-blocking agents (C07), calcium channel blockers (C08, C07FB, 
C09BB, C09DB), imidazoline receptor blockers (C02AC), prazosin (C02CA01) and minoxidil 
(C02DC01). Individuals taking single-pill combinations of antihypertensive drugs were 
counted as taking separate classes of each drug. 
 
RH was defined as above-goal elevated BP despite the concurrent use of three or more 
antihypertensive drug classes, one of which was a diuretic or controlled BP by using four or 
more antihypertensive drugs (5). The BP treatment goals were based on the ADA guidelines 
(25, 26). About two-third of the individuals had their baseline visit in 2000 or before. Therefore, 
in the main analysis the BP threshold was set <130/85 mmHg, which was the recommended 
BP target for individuals with diabetes at the time when most of the BP measures were obtained 
(25). Thus, controlled BP was defined as BP <130/85 mmHg and uncontrolled as BP ≥130/85 
mmHg (25). In addition, supplementary analysis was applied by more stringent BP target of 
<130/80 mmHg, which was the target between 2001 and 2012 (26) and is currently also the 
recommended target for individuals with diabetes according to the American College of 
Cardiology and the American Heart Association (27). We identified 1,103 individuals from the 
FinnDiane cohort, who were taking antihypertensive medication 6 months before and after the 
baseline visit. We divided them into three groups: (a) RH (uncontrolled BP despite concurrent 
use of ≥3 antihypertensive drugs of different classes, one of which is a diuretic or controlled 
BP, but require ≥4 antihypertensive drugs), (b) no RH (uncontrolled BP with ≤2 
antihypertensive drugs or with 3 drugs, one of which is not a diuretic) and (c) controlled BP, 
with ≤ 3 antihypertensive drugs.  
 
Statistical analysis 
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Data are expressed as means ± SD for normally distributed variables, as medians with 
interquartile range for non-normally distributed values and binary variables as percentages. 
The statistical significance differences between two groups for normally distributed variables 
were tested by using ANOVA, otherwise with Kruskal-Wallis tests. Categorical variables were 
tested with Pearson’s ꭓ2 test or two-tailed Fisher’s exact test. The cumulative incidence of DN 
progression, incident CHD and stroke, and all-cause mortality was estimated using the Kaplan-
Meier method and the log-rank test was used to test the differences between the study groups.  
 
Cox proportional hazard regression models were used to calculate the HR for each outcome 
separately. The results are presented as HR with 95% CI. The multivariable models were 
adjusted for sex, age, current and history of smoking, WHR, triacylglycerol, HbA1C, previous 
CHD, previous stroke, DN status and renal function, when applicable. The time-dependent 
effects of the variables were tested by using the Schoenfeld residuals against the follow-up 
time. When the Cox proportional hazard assumption was violated, the models were fitted in 
two different ways. If an effect of an independent variable was time-varying, the variable was 
stratified. Continuous measurements were categorized, if applicable (see Table 2 and Suppl. 
Tables S1-S7). If an effect of the dependent variable was time-varying, follow-up time was 
stratified into distinct intervals, following the method of Zhang et al. (28) (Suppl. App.1). 
Separate models were applied for the two DN status and renal function groups, as well as for 
men and women separately, and finally as using a BP threshold <130/80 mmHg. All statistical 
analyses were performed with the R project statistical software, version R 3.5.3 (29).  
 
Results 
 
Characteristics of study population 
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This study comprised 1,103 individuals with type 1 diabetes, who were on antihypertensive 
treatment at baseline, 56% of whom were men. The mean age was 43.7 ± 10.4 years and 
diabetes duration 26.3 ± 9.7 years. Almost one-third of the individuals had decreased renal 
function (eGFR <60 ml/min/1.73 m2) and more than 40% had DN (AER ≥200 µg/min or ≥300 
mg/24h). The prevalence of RH was 18.7%, 57.9% had uncontrolled BP, but no RH, and 23.4% 
had controlled BP. In this cohort, only seven individuals with RH had controlled BP, but 
required ≥4 antihypertensive drugs. About one-quarter of the individuals with RH were taking 
three antihypertensive drugs, including an ACE inhibitor, a diuretic and a calcium channel 
blocker. Similarly, one-quarter of them were taking 4 drugs, combined also with β-blocking 
agents. Half of the individuals with no RH and about 60% of those with controlled BP were 
taking only one drug. The prevalence of RH was higher in men than in women (22.5% vs. 
13.7%). With the more stringent BP target (<130/80 mmHg) the prevalence of individuals with 
RH (19.2%) increased, while that of controlled BP (15.3%) decreased.  
 
The characteristics of the individuals with respect to the three groups (RH, no RH, controlled 
BP) are presented in Table 1. Those with RH showed the highest prevalence of DN and more 
often reduced renal function than those with controlled BP. They had also worse lipid profile 
and higher WHR, as well as worse glycemic control and lower insulin sensitivity than those 
with controlled BP. No differences were observed regarding smoking and prevalence of 
previous CHD. Individuals with no RH had also a worse clinical profile than those with 
controlled BP. However, no differences were observed in glycemic control, HDL cholesterol, 
DN status, renal function, smoking and previous cardiovascular events.  
 
During a median of 14.8 (IQR 11.9; 17.0) follow-up years (15,082 person-years), in total 321 
(29.1%) individuals progressed to a higher level of albuminuria or ESRD, 239 (21.7%) 
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experienced an incident CHD, and 138 (12.5%) an incident stroke. Moreover, in total 302 
individuals died (27.4%) during the follow-up. Crude event rates and Kaplan-Meier estimates 
were the highest in those with RH, compared with those who had no RH or controlled BP.  
 
Risk of DN progression 
The 15-year cumulative risk of DN progression was the highest in those with RH (56.6% [95% 
CI 48.6, 63.3], p<0.0001), while no differences in risk were observed between those with no 
RH (24.9% [21.2, 28.5], p=0.9) and controlled BP (25.0% [19.4, 30.3] (Figure 1A). Table 2 
shows the unadjusted and multivariable Cox proportional hazards models for these three groups 
and severe outcomes. After adjusting for all covariates, the risk of DN progression remained 
nearly two times higher in those with RH (HR 1.95 [95% CI 1.37, 2.79] compared with those 
who had controlled BP. The risk was even higher in those with macroalbuminuria and RH (2.17 
[1.41, 3.34] (Suppl. Table S4) and in those with eGFR <60 ml/min/1.73 m2 (2.00 [1.24, 3.22] 
(Suppl. Table S6). Men with RH had an almost two times higher risk of progression compared 
with those who had controlled BP (Suppl. Table S1). However, in women the effect of the no 
RH was time-varying, and therefore, time-adjusted analysis was performed, showing a two-
fold higher risk only after 4.2 years of follow-up  in those with RH, compared with those who 
had controlled BP (Suppl. App.1, 2E). Finally, with the more stringent BP target, the 
association between DN progression and RH remained higher after full adjustments (Suppl. 
Table S7). 
 
Risk of cardiovascular events 
In those with RH, the 15-year cumulative risk of CHD was 35.1% (95% CI 27.1, 42.3, 
p<0.0001), while the risk was 24.8% (21.0, 28.5, p=0.0003) in those with no RH and 12.8% 
(8.1, 17.3) in those with controlled BP (Figure 1B). Similarly, the risk of stroke was 24.2% 
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(17.0, 31.1, p<0.0001), 14.2% (11.1, 17.1, p=0.008) and 7.3% (3.9, 10.6), respectively (Figure 
1C). After adding kidney disease markers (i.e. stages of DN and renal function) into the 
multivariable Cox models, no differences were observed between the groups and the CHD risk 
(Table 2). Because the kidney disease markers were strong predictors in the models, we also 
stratified the individuals into two DN status and two renal function groups. These stratifications 
as well as the stratification by sex (Suppl. Tables S1-S6) showed no differences between the 
individuals with RH and those who had controlled BP.  
 
After adjusting for clinical confounders, including DN status (Table 2), RH was associated 
with stroke (HR 2.00 [95% CI 1.07, 3.71]. However, this association disappeared after further 
adjustment for renal function. A similar pattern was seen when women were separately 
analyzed; the higher stroke risk in those with RH remained in the presence of clinical 
confounders, but no differences were observed between the groups after additional adjustment 
for renal function (Suppl. Table S2). Importantly, before the development of macroalbuminuria 
the risk of stroke was 3.5-fold higher in those with RH compared with those who had controlled 
BP, while those with no RH did not differ from those with controlled BP (Suppl. Table S3). 
With the BP target <130/80 mmHg, the risk estimates of incident CHD and stroke were slightly 
lower and when accounting for clinical confounders the differences disappeared even earlier 
(Suppl. Table S7).  
 
The risk of all-cause mortality 
The 15-year cumulative risk of all-cause mortality was 42.9% (95% CI 35.4, 47.1, p <0.0001) 
in those with RH, 25.7% (22.0, 29.1, p=0.002) in those with no RH and 16.7% (12.7, 20.5) in 
those with controlled BP (Figure 1D). After adjusting for clinical confounders, RH was 
associated with all-cause mortality compared to those with controlled BP, while no differences 
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were observed in those with no RH compared to those who had controlled BP (Table 2). 
However, when kidney disease markers were added into the multivariable models, there were 
no differences between the groups. The risk of death did not differ when comparing RH or no 
RH and controlled BP groups within the DN strata (Suppl. Tables S3, S4). However, when we 
divided the individuals into two renal function groups, the risk remained slightly higher in those 
with RH, who had an eGFR ≥60 ml/min/1.73 m2 compared with those who had controlled BP 
(Suppl. Table S5). Also, in women the risk of all-cause mortality was 90% higher in those with 
RH compared to those with controlled BP when adjusting for potential confounders (Suppl. 
Table S2). With the more stringent BP target (i.e. 130/80 mmHg), the risk estimates of all-
cause mortality did not change and, again, when kidney disease markers were added into the 
model, the difference disappeared (Suppl. Table S7). 
 
Conclusions 
 
Our findings from the nationwide FinnDiane cohort with type 1 diabetes shows that RH is 
associated with an increased risk of incident CHD, incident stroke and all-cause mortality, 
which were, however, attenuated after adjusting for clinical confounders, and disappeared 
when kidney disease markers were added into the models. This is in line with clinical findings 
showing a strong association between RH and DN that in turn is known to be a dominant 
contributor to excess cardiovascular mortality (30).  
 
Another important finding is that the presence of RH is independently related to greater risk of 
DN progression, especially in individuals with advanced DN. Only a few previous studies have 
reported similar associations between RH and renal outcomes in a CKD population. A 
multicenter study (N=788) demonstrated that RH was associated with a 2.3-fold higher risk of 
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ESRD (31). Another study (N=3367) (32) reported that individuals with RH had almost 30% 
higher risk of renal complications after 5-year follow-up. Moreover, among individuals with 
type 2 diabetes and CKD from 90 diabetes centers in Italy (N=2778), RH was related to higher 
risk of eGFR loss (>30% reduction from baseline) during a 4-year follow-up (17). Despite 
differences in study populations, definitions of RH and follow-up times, our findings together 
with these earlier studies highlight the importance of recognition of RH in individuals with 
kidney disease. 
 
Previous studies have demonstrated the difficulties to control BP at the late stages of kidney 
disease both in the general CKD population and in individuals with type 1 diabetes (3, 33). 
Several mechanisms may contribute to the development of treatment resistance in individuals 
with kidney disease. Reduced kidney function causes impaired salt excretion, over-activation 
of the renin-angiotensin-aldosterone system and increased sympathetic nervous system activity. 
These factors in turn lower the response to antihypertensive therapy (5). As RH and advanced 
kidney disease is a challenging combination, robust evidence on their close relationship in 
various clinical conditions such as in type 1 diabetes, is urgently needed in order to be able to 
identify the risk individuals that should be provided optimal clinical care and counseling as 
early as possible (30). Furthermore, clinical controlled trials should be carried out in order to 
find out the best means to optimize the management of RH throughout the kidney disease 
spectrum (e.g. the optimum BP targets and drug combinations, the efficacy of procedures and 
device-based therapies, such as carotid baroreceptor activation) (30). In fact, we are currently 
investigating a device-based therapy, baroreflex activation therapy, with results to be expected 
within two years (34).  
 
14 
 
Notably, we found that those with normal AER and microalbuminuria with RH had 3.5 times 
higher risk of stroke, compared with those who had controlled BP. It is well known that 
hypertension is one of the strongest risk factors for stroke, both in the general population (35) 
and in type 1 diabetes (19, 36). The risk of stroke increases after BP exceeds 130/80 mmHg in 
individuals with type 2 diabetes (37), while among individuals with type 1 diabetes a linear 
increase in systolic BP is observed even earlier (19). Therefore, our findings indicate that it 
would be important to identify the individuals with RH early to lower their BP aggressively 
with efficient pharmacotherapy, as well as to improve their adherence to the treatment, and to 
pay attention to lifestyle factors to achieve the recommended BP treatment targets (38). 
Numerous studies have suggested that BP control may be less effective in individuals with RH 
than in those without RH which might be related to differences in the 24-h BP-profiles, 
differences in the pathophysiology of RH, or greater degrees of target organ damage (5). In the 
future, pharmacogenomics may provide a more rational and personalized targeted approach to 
the treatment of individuals with RH (5). The benefit of device-based therapies for improving 
the prognosis of individuals with RH still needs clarification (5, 39). 
 
The target BP values have been debated for several years and also revised several times. As a 
consequence, there is variation in the diabetes guidelines regarding the definition of normal BP 
in individuals with type 1 diabetes. The current ADA guidelines have set the threshold of BP 
to 140/90 mmHg, but a more stringent target is recommended for high risk individuals. Lately, 
the American College of Cardiology and the American Heart Association published new 
guidelines for hypertension (28). They suppose that the majority of patients with diabetes 
would fit into the high-risk category (10-year cardiovascular risk >10%) and thus, the new 
guidelines recommend a more stringent office BP goal (<130/80 mmHg). A recent revision of 
the AHC Scientific Statement on the definition of RH, recommends that in addition to a diuretic, 
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the anti-hypertensive regimen should also include a long-acting calcium channel blocker and a 
blocker of the renin-angiotensin system (5). In our cohort 68% had at least these three drugs in 
their regimen.  
 
The main strength of our study is that all participants were carefully characterised regarding 
their medical history as well as the presence and development of diabetic complications as part 
of the nationwide, multicenter, FinnDiane study. It is also of note that we were able to link 
longitudinal data with several high-quality national registers. To our knowledge, this is the first 
large scale study that assesses severe outcomes related to RH in individuals with type 1 diabetes. 
The main limitations relate to the definition of RH. First, the BP values were based on two 
office-based measurements at a single baseline visit. Consequently, white-coat and masked 
hypertension were not assessed. Second, we cannot exclude that our results are affected by 
residual confounding e.g. follow-up measurements of BP during the follow-up time were not 
available, and BP could change over time. However, our study population is well characterized 
and the set of covariates were chosen carefully based on the literature. Moreover, although the 
accuracy and coverage of the Finnish Drug Register is high, medication doses are not recorded 
and, therefore, we were not able to confirm, whether the antihypertensive drugs were 
administered at the maximum tolerated doses. However, the drug register is unique enabling 
careful characterization of the types of medication purchased from the pharmacies. Finally, 
adherence to treatment could not be assessed. Therefore, because the definition of resistant 
hypertension represents apparent rather than true treatment-resistant hypertension, our results 
may overestimate the true prevalence of treatment-resistant hypertension.  
 
In conclusion, this nationwide FinnDiane study showed that RH is associated with a higher risk 
of DN progression in individuals with type 1 diabetes, and especially in those with 
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macroalbuminuria. However, RH did not predict incident CHD and stroke or death, beyond 
albuminuria and reduced kidney function. Importantly, in those with normal AER and 
microalbuminuria, RH was associated with 3.5 times higher risk of stroke compared to those 
with controlled BP, while no differences were observed between those with no RH and 
controlled BP. Therefore, our data suggest that diagnostic and therapeutic counseling should 
be provided to these very high risk individuals with RH in order to decrease their risk of adverse 
events. 
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Table 1. Baseline characteristics of the study participants (N=1,103)  
Characteristics Resistant 
hypertension 
(n=206 / 18.7%) 
P value No RH (n=639 / 
57.9%) 
P value Controlled BP 
(n=258 /23.4%) 
Men (%) 68.0 <0.0001 57.3 0.0007 44.6 
Age (years) 45.6 ± 10.3 <0.0001 44.2 ± 11.3 <0.0001 39.4 ± 10.3 
Age at onset of diabetes 
(years) 
13.0 (9.0–21.0) 0.01 14.0 (9.0–22.0) 0.002 12.0 (7.0–17.0) 
Diabetes duration 
(years) 
30.0 ± 8.4 <0.0001 28.7 ± 10.8 0.0005 26.1 ± 9.9 
Systolic BP (mmHg) 154 ± 20 <0.0001 147 ± 15 <0.0001 120 ± 8 
Diastolic BP (mmHg) 85 ± 10 <0.0001 84 ± 10 <0.0001 74 ± 7 
BMI (kg/m2) 26.5 ± 3.6 0.0005 25.9 ± 3.6 0.02 25.3 ± 3.9 
Waist circumference 
(cm) 
92.8 ± 13.0 <0.0001 89.3 ± 11.1 <0.0001 85.4 ± 12.1 
Waist-to-hip ratio 0.92 ± 0.09 <0.0001 0.89 ± 0.08 <0.0001 0.86 ± 0.08 
Hemoglobin A1C (%) 8.9 ± 1.5 0.04 8.6 ± 1.4 0.9 8.6 ± 1.5 
Hemoglobin A1C  
(mmol/mol) 
74 ± 16 0.04 70 ± 16 0.9 70 ± 16 
Total cholesterol 
(mmol/L) 
5.37 ± 1.22 0.001 5.16 ± 0.87 0.03 5.01 ± 0.95 
HDL cholesterol 
(mmol/L) 
1.18 ± 0.39 0.0003 1.31 ± 0.38 0.7 1.32 ± 0.38 
LDL cholesterol 
(mmol/L) 
3.33 ± 0.92 0.008 3.26 ± 0.82 0.01 3.10 ± 0.86 
Triglycerides (mmol/l) 1.45 (1.09–2.30) <0.0001 1.13 (0.81–1.66) 0.02 1.02 (0.79–1.44) 
eGDR* (mg kg-1 min-1) 4.0 ± 1.4 <0.0001 4.6 ± 1.4 0.0007 4.9 ± 1.4 
Lipid-lowering 
treatment (%) 
31.1 <0.0001 20.5 0.01 12.8 
Nephropathy status (%)  <0.0001  0.5  
Normal AER † 14.6 NA 34.6 NA 32.6 
Microalbuminuria 11.1 NA 29.3 NA 32.9 
Macroalbuminuria 74.3 NA 36.1 NA 34.5 
eGFR (ml/min/1.73 m2) 43.3 (23.8–67.2) <0.0001 80.5 (61.5–96.4) 0.2 82.6 (61.6–101.7) 
Renal status (%)  <0.0001  0.3  
eGFR >90  12.1 NA 34.2 NA 38.8 
eGFR 60 – 90 20.4 NA 42.4 NA 37.3 
eGFR <60 67.5 NA 23.4 NA 23.9 
Laser treatment (%) 76.7 0.0004 56.9 0.3 60.7 
Current smoker (%) 20.6 0.3 22.6 0.5 25.1 
History of CHD (%) 11.6 0.3 6.6 0.4 8.5 
History of stroke (%) 7.3 0.0005 3.1 0.07 0.8 
Number of the 
antihypertensive drugs 
(mean) 
3.4 ± 0.5 <0.0001 1.4 ± 0.5 0.6 1.4 ± 0.7 
1 drug (%) NA NA 60.1 NA 66.7 
2 drugs (%) NA NA 37.4 NA 22.1 
3 drugs (%) 63.1 NA 2.5 NA 11.2 
≥4 drugs (%) 36.9 NA NA NA NA 
Data are mean ±SD, median (interquartile range) or %. P values represent comparisons with 
controlled BP group. *eGDR, estimated glucose disposal rate, †AER, albumin excretion rate 
 
22 
 
Table 2. Cox regression models for DN progression, incident CHD and stroke, and all-cause mortality according to the three groups: RH, no RH and controlled 
BP in individuals with type 1 diabetes  
 Model 1 Model 2 Model 3 Model 4 Model 5 
DN progression      
N=1103, 321 events)      
RH (see Suppl. Fig. 1A)* (see Suppl. Fig. 1B)* 3.07 (2.16, 4.37), <0.0001 2.41 (1.68, 3.44), <0.0001 1.95 (1.37, 2.79), 0.0002 
No RH (see Suppl. Fig. 1A)* (see Suppl. Fig. 1B)* 1.07 (0.79, 1.44), 1.0 0.99 (0.72,1.36), 0.9 1.05 (0.76, 1.44), 0.8 
Controlled BP (see Suppl. Fig. 1A)* (see Suppl. Fig. 1B)* ref. ref. ref. 
Incident CHD      
(N=1015, 321 events)      
RH 2.92 (1.91, 4.47), <0.0001 2.13 (1.38, 3.30), 0.0007 1.76 (1.11. 2.81), 0.02 1.55 (0.97, 2.47), 0.06 1.48 (0.92, 2.37), 0.1 
No RH 1.98 (1.36, 2.88), 0.0004 1.47 (1.00, 2.16), 0.05 1.39 (0.93, 2.08), 0.1 1.41 (0.95, 2.11), 0.09 1.42 (0.95, 2.13), 0.08 
Controlled BP ref. ref. ref. ref. ref. 
Incident stroke      
(N=1066, 138 events)      
RH 3.73 (2.13, 6.51), <0.0001 2.84 (1.61, 5.01),.0003 2.56 (1.40, 4.68), 0.002 2.00 (1.07, 3.71), 0.03 1.67 (0.90, 3.12), 0.1 
No RH 1.96 (1.17, 3.27), 0.01 1.56 (0.93, 2.62), 0.09 1.59 (0.93, 2.71), 0.9 1.61 (0.95, 2.75), 0.08 1.69 (0.99, 2.88), 0.05 
Controlled BP ref. ref ref ref. ref. 
All-cause mortality       
(N=1103, 302 deaths)      
RH 3.33 (2.32, 4.80), <0.0001 2.51 (1.73, 3.64), <0.0001 1.72 (1.16, 2.56), 0.007 1.35 (0.91, 2.02), 0.1 1.26 (0.84, 1.88), 0.3 
No RH 1.70 (1.21, 2.39), 0.002 1.31 (0.92, 1.84), 0.3 1.18 (0.83, 1.68), 0.3 1.16(0.82, 1.66 ), 0.4 1.17 (0.82, 1.67), 0.4 
Controlled BP ref. ref. ref. ref. ref. 
Data are HR (95% CI) and P values (Controlled BP reference group); *Time-varying effect of dependent variable 
Model 1: Unadjusted;  
Model 2: Adjusted for age and sex 
Model 3: Model 2 + HbA1C, WHR, Triglycerides, smoking and previous CHD and/or previous stroke 
Model 4: Model 3 + nephropathy status (Normal AER, microalbuminuria, macroalbuminuria) 
Model 5: Model 4 + eGFR / Renal stage group (eGFR >90, 60-90 and <60 ml/min/1.73 m2) 
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Figure legends 
 
Figure 1. 15-year cumulative risk of DN progression (A), incident CHD (B), incident stroke (C) and all-cause 
mortality (D) in those with controlled BP (dotted line), with no RH (dashed line) and with RH (solid line) in 
individuals with type 1 diabetes 
 
Supplementary (Suppl.) Table 1. Cox regression models for DN progression, incident CHD and stroke, and all-cause mortality according to the three 
groups: RH, no RH and controlled BP in men with type 1 diabetes; RH 140 (22.5%); no RH 366 (58.9%); Controlled BP 115 (18.5%) 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
 
Model 1: Unadjusted 
Model 2: Adjusted for age/age group (age ≤35, 36-45, 46-55 and >55 years) 
Model 3: Model 2 + HbA1C, WHR, triglycerides, smoking and previous CHD and/or previous stroke 
Model 4: Model 3 + nephropathy status 
Model 5: Model 4 + eGFR/renal stage group (eGFR >90, 60-90 and <60 ml/min/1.73 m2) 
 
 
 
 
 
 
 
 
 
 
 
 Model 1 Model 2 Model 3 Model 4 Model 5 
DN progression  (N=621,  189 events) 
RH 3.34 (2.14, 5.23), <0.0001 3.70 (2.35, 5.83),<0.0001  2.70 (1.67, 4.35), <0.0001 2.21 (1.36, 3.59), 0.001 1.98 (1.21, 3.24), 0.006 
No RH 1.06 (0.69, 1.65), 0.8 1.13 (0.73, 1.75), 0.6 1.05 (0.67, 1.66), 0.8 1.05 (0.67, 1.64), 0.8 1.14 (0.72, 1.80), 0.6 
Controlled BP Reference Reference Reference Reference  Reference  
Incident CHD (N=564, 132 events) 
RH 2.52 (1.36, 4.67), 0.003 2.03 (1.09, 3.77), 0.02  1.73 (0.89, 3.36), 0.1  1.45 (0.74, 2.83), 0.3 1.41 (0.72, 2.78), 0.2 
No RH 1.82 (1.03, 3.22), 0.04 1.49 (0.84, 2.64), 0.2 1.44 (0.79, 2.62), 0.2 1.45 (0.80, 2.65), 0.2 1.46 (0.80, 2.65), 0.3 
Controlled BP Reference Reference Reference Reference Reference 
Incident stroke (N=599, 92 events) 
RH 2.26 (1.17, 4.37),  0.01 2.04 (1.05, 3.95), 0.03 2.00 (0.98, 4.12), 0.06 1.48 (0.70, 3.14), 0.3 1.21 (0.56, 2.62), 0.6 
No RH 1.28 (0.70, 2.36), 0.4 1.17 (0.63, 2.15 ), 0.6 1.30 (0.69, 2.48), 0.4 1.30 (0.69, 2.48), 0.4 1.27 (0.67, 2.41), 0.5 
Controlled BP Reference Reference Reference Reference Reference 
All-cause mortality (N=621, 181 deaths) 
RH  2.16 (1.35, 3.46), 0.001 1.87 (1.17, 2.99), 0.009 1.33 (0.81, 2.21), 0.2 0.95 (0.57, 1.58), 0.8 0.86 (0.51, 1.47), 0.6 
No RH  1.24 (0.80, 1.93), 0.3 1.10 (0.71, 1.71), 0.7 1.04 (0.66, 1.63), 0.9 1.00 (0.64, 1.57), 1.0 0.99 (0.63, 1.56), 1.0 
Controlled BP Reference Reference Reference Reference Reference 
Suppl. Table 2. Cox regression models for DN progression, incident CHD and stroke, and all-cause mortality according to the three groups: RH, no RH and 
controlled BP in women with type 1 diabetes; RH 66 (13.7%), no RH (56.6%), controlled BP 143 (29.7%) 
Data are HR (95% CI) and p-values (Controlled BP reference group). *Time-varying effect of dependent variable. 
 
Model 1: Unadjusted 
Model 2: Adjusted for age/age group (age ≤35, 36-45, 46-55 and >55 years)  
Model 3: Model 2 + HbA1C, WHR, triglycerides, smoking and previous CHD and/or previous stroke 
Model 4: Model 3 + nephropathy status 
Model 5: Model 4 + eGFR/renal stage (eGFR >90, 60-90 and <60 ml/min/1.73 m2) 
 
 
 
 
 
 
 
 
 
 
 Unadjusted Model 1 Model 2 Model 3 Model 4 
DN progression ( N=482, 132 events) 
RH 
No RH 
Controlled BP 
 
(see Suppl. Fig. 2A)* 
 
 
 (see Suppl. Fig. 2B)* 
 
 (see Suppl. Fig. 2C)* 
 
 (see Suppl. Fig. 2D)* 
 
 (see Suppl. Fig. 2E)* 
Incident CHD (N=451, 107 events) 
RH 
No RH 
Controlled BP 
 (see Suppl. Fig. 3A)*  (see Suppl. Fig. 3B)*  (see Suppl. Fig. 3C)*  (see Suppl. Fig. 3D)*  (see Suppl. Fig. 3E)* 
Incident stroke ( N=465, 46 events) 
RH 7.15 (2.51, 20.31),  0.0002 5.54 (1.91, 16.09),0.002 4.16 (1.37, 12.60), 0.01 3.09 (1.01, 9.46), 0.05 2.44 (0.78, 7.66), 0.1 
No RH 3.39 (1.31, 8.75), 0.01 2.63 (0.99, 6.98 ), 0.05 2.38 (0.89, 6.38), 0.08 2.38 (0.89, 6.36), 0.08 2.34 (0.88, 6.28), 0.09 
Controlled BP Reference Reference Reference Reference Reference 
All-cause mortality ( N=482, 121 deaths) 
RH  5.66 (3.17, 10.10), <0.0001 3.97 (2.18, 7.22), <0.0001 2.59 (1.34, 4.99), 0.004 2.26 (1.18, 4.35), 0.01 1.95 (1.02, 3.75), 0.04 
No RH  2.35 (1.38, 4.00), 0.002 1.78 (1.02, 3.08), 0.04 1.43 (0.80, 2.55), 0.2 1.46 (0.82, 2.61), 0.2 1.78 (0.99, 3.18), 0.05 
Controlled BP Reference Reference Reference Reference Reference 
Suppl. Table 3. Cox regression models for DN progression, incident CHD and stroke, and all-cause mortality according to the three groups: RH, no RH and 
controlled BP in individuals with normal AER or microalbuminuria and type 1 diabetes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are HR (95% CI) and p-values (Controlled BP reference group). *Time-varying effect of dependent variable. 
 
Model 1: Unadjusted 
Model 2: Adjusted for age/age group (age ≤35, 36-45, 46-55 and >55 years) and sex 
Model 3: Model 2 + HbA1C, WHR/WHR group (men WHR <0.95, 0.96-0.99, ≥1.0; women WHR <0.80, 0.81-0.85, ≥0.86), triglycerides, smoking and 
previous CHD and/or previous stroke 
Model 4: Model 3 + eGFR/renal stage (eGFR >90, 60-90 and <60 ml/min/1.73 m2) 
                    
 
 
 
 
 
 
 
 
 Model 1 Model 2 Model 3 Model 4 
DN progression (N=630, 95 events) 
RH 
No RH 
Controlled BP 
(see Suppl. Fig. 4A)*  (see Suppl. Fig. 4B)* 
0.51 (0.16, 1.61), 0.2 
0.87 (0.51, 1.50), 0.6 
Reference 
0.50 (0.16, 1.58), 0.2 
0.87 (0.50, 1.49), 0.6 
Reference 
Incident CHD (N=573, 100 events) 
RH 3.74 (1.68, 8.33), 0.001 1.85 (0.81, 4.25), 0.1 1.52 (0.64, 3.63), 0.3  1.51 (0.63, 3.60), 0.3 
No RH 2.78 (1.51, 5.11), 0.001 1.84 (0.99, 3.45), 0.05 1.67 (0.88, 3.15), 0.1 1.69 (0.89, 3.19), 0.1 
Controlled BP Reference Reference Reference Reference 
Incident stroke (N=616, 56 events) 
RH 4.99 (1.81, 13,78),  0.002 3.19 (1.13, 8.97),0.03 3.55 (1.22, 10.35), 0.02 3.49 (1.20, 10.15), 0.02 
No RH 2.60 (1.17, 5.81), 0.02 1.95 (0.86, 4.39), 0.1 2.01 (0.88, 4.58), 0.1 2.01 (0.89, 4.58), 0.09 
Controlled BP Reference Reference Reference Reference 
All-cause mortality (N=630, 109 deaths) 
RH 2.93 (1.49, 5.76), 0.002 1.48 (0.74, 2.99), 0.3 1.44 (0.66, 3.10), 0.3 1.32 (0.61, 2.88), 0.5 
No RH 1.70 (1.02, 2.81), 0.04 1.15 (0.69, 1.93), 0.6 1.30 (0.77, 2.19), 0.3 1.32 (0.78, 2.22), 0.3 
Controlled BP Reference Reference Reference Reference 
Suppl. Table 4. Cox regression models for DN progression, incident CHD and stroke, and all-cause mortality according to the three groups: RH, 
no RH and controlled BP in individuals with macroalbuminuria and type 1 diabetes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are HR (95% CI) and p-values (Controlled BP reference group). *Time-varying effect of dependent variable. 
 
Model 1: Unadjusted 
Model 2: Adjusted for age and sex 
Model 3: Model 2 + HbA1C, WHR/WHR group (men WHR <0.95, 0.96-0.99, ≥1.0; women WHR <0.80, 0.81-0.85, ≥0.86), triglycerides /triglycerides control 
(triglycerides <2.3, 2.3-4.5, and >4.5 mmol/l), smoking and previous CHD and/or previous stroke 
Model 4: Model 3 + eGFR/renal stage (eGFR >90, 60-90 and <60 ml/min/1.73 m2) 
 
 
 
 
 
 
 
 
 
 Model 1 Model 2 Model 3 Model 4 
DN progression  (N=473, 226 events) 
RH 2.91 (1.98, 4.28), <0.0001 3.35 (2.24, 5.01), <0.0001 3.18 (2.05, 4.93), <0.0001 2.17 (1.41, 3.34), 0.0004 
No RH 0.95 (0.64, 1.41), 0.8 1.02 (0.69, 1.53), 0.9 1.01 (0.66, 1.55), 1.0 0.99 (0.64, 1.51), 0.9 
Controlled BP Reference Reference Reference Reference  
Incident CHD (N=442, 139 events)  
RH 
No RH 
1.84 (1.10, 3.07), 0.02 
1.51 (0.93, 2.46), 0.1 
(see Suppl. Fig. 5A)* 
1.40 (0.80, 2.45), 0.2  
1.18 (0.70, 2.00), 0.5 
1.32 (0.75, 2.33), 0.3 
1.18 (0.69, 1.99), 0.5 
Controlled BP Reference  Reference Reference 
Incident stroke (N=450, 82 events) 
RH 2.18 (1.10, 4.33),  0.03 1.62 (0.80, 3.29), 0.2 1.50 (0.69, 3.23), 0.3 1.12 (0.51, 2.45), 0.8 
No RH 1.54 (0.79, 3.01), 0.2 1.25 (0.63, 2.47), 0.5 1.25 (0.61, 2.55), 0.5 1.31 (0.64, 2.69), 0.5 
Controlled BP Reference Reference Reference Reference 
All-cause mortality (N=473, 193 deaths) 
RH 2.41 (1.51, 3.83), 0.0002 1.83 1.13, 2.95), 0.01 1.32 (0.79, 2.20), 0.3 1.14 (0.68, 1.93), 0.6 
No RH 1.71(1.08, 2.70), 0.02 1.32 (0.82, 2.11), 0.2 1.17 (0.72, 1.90), 0.5 1.19 (0.73, 1.93), 0.5 
Controlled BP Reference Reference Reference Reference 
 Suppl. Table 5. Cox regression models for DN progression, incident CHD and stroke, and all-cause mortality according to the three groups: RH, no RH and 
controlled BP in individuals with eGFR ≥ 60 ml/min/1.73 m2 and type 1 diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are HR (95% CI) and p-values (Controlled BP reference group). *Time-varying effect of dependent variable. 
 
Model 1: Unadjusted 
Model 2: Adjusted for age/age group (age ≤35, 36-45, 46-55 and >55 years) and sex 
Model 3: Model 2 + HbA1C/glycemic control (HbA1C <7.5, 7.5-8.99; >9.0 %), WHR, triglycerides, smoking and previous CHD and/or previous stroke  
Model 4: Model 3 + eGFR/renal stage (eGFR >90, 60-90 and <60 ml/min/1.73 m2) 
 
 
 
 
 
 
 
 
 
 
 
 Model 1 Model 2 Model 3 Model 4 
DN progression (N=749, 111 events) 
RH 
No RH 
 
(see Suppl. Fig. 6A)* 
 
(see Suppl. Fig. 6B)* 
 
(see Suppl. Fig. 6C)* 
 
(see Suppl. Fig. 6D)* 
Controlled BP     
Incident CHD (N=703, 132 events) 
RH 2.45 (1.20, 5.01), 0.01 1.57 (0.75, 3.27), 0.2 1.40 (0.64, 3.06), 0.4  1.26 (0.57, 2.80), 0.6 
No RH 2.48 (1.50, 4.10), 0.0004 1.82 (1.09, 3.06), 0.02 1.77 (1.03, 3.03), 0.04 1.81 (1.05, 3.11), 0.03 
Controlled BP Reference Reference Reference Reference 
Incident stroke (N=735, 59 events)  
RH 2.64 (0.91, 7.61),  0.07 1.91 (0.65, 5.62), 0.2 2.30 (0.77, 6.92), 0.1 2.48 (0.82, 7.50), 0.1 
No RH 2.46 (1.16, 5.22), 0.02 1.98 (0.92, 4.26), 0.08 2.05 (0.95, 4.44), 0.07 2.16 (1.00, 4.68), 0.05 
Controlled BP Reference Reference Reference Reference 
All-cause mortality (N=749, 136 deaths) 
RH 3.25 (1.76, 6.01), 0.0002 2.15 (1.15, 4.02), 0.02 2.20 (1.13, 4.31), 0.02 2.04 (1.04, 4.02), 0.04 
No RH 1.91 (1.19, 3.07), 0.007 1.43 (0.88, 2.32), 0.1 1.48 (0.90, 2.45), 0.1 1.50 (0.91, 2.48), 0.1 
Controlled BP Reference Reference Reference Reference 
Suppl. Table 6. Cox regression models for DN progression, incident CHD and stroke, and all-cause mortality according to the three groups: RH, no RH and 
controlled BP in individuals with eGFR < 60 ml/min/1.73 m2 and type 1 diabetes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
 
Model 1: Unadjusted 
Model 2: Adjusted for age/age group (age ≤35, 36-45, 46-55 and >55 years) and sex 
Model 3: Model 2 + HbA1C, WHR, triglycerides/ triglycerides control (triglycerides <2.3, 2.3-4.5, and >4.5 mmol/l), smoking and previous CHD and/or 
previous stroke  
Model 4: Model 3 + eGFR/renal stage (eGFR >90, 60-90 and <60 ml/min/1.73 m2) 
 
 
 
 
 
 
 
 
 Model 1 Model 2 Model 3 Model 4 
DN progression (N=349, 210 events) 
RH 1.96 (1.33, 2.89), 0.0007 2.13 (1.43, 3.18), 0.0002 2.25 (1.45, 3.47), 0.0003 2.00 (1.24, 3.22), 0.004 
No RH 0.81 (0.54, 1.22), 0.3 0.88 (0.58, 1.33), 0.5 0.95 (0.61, 1.47), 0.8 1.00 (0.62, 1.62), 1.0 
Controlled BP Reference Reference Reference Reference  
Incident CHD (N=308, 107 events) 
RH 1.71 (0.95, 3.05), 0.07 1.46 (0.81, 2.63), 0.2 1.31 (0.70, 2.44), 0.4 1.21 (0.64, 2.26), 0.5 
No RH 1.38 (0.77, 2.47), 0.3 1.10 (0.61, 1.99), 0.7 0.91 (0.49, 1.71), 0.8 0.87 (0.47, 1.64), 0.7 
Controlled BP Reference Reference Reference Reference 
Incident stroke (N=326, 78 events)  
RH 1.87 (0.92, 3.79),  0.08 1.57 (0.77, 3.21),0.2 1.53 (0.72, 3.27), 0.3 1.36 (0.63, 2.96), 0.4 
No RH 1.53 (0.75, 3.09), 0.2 1.30 (0.64, 2.63), 0.5 1.43 (0.68, 3.03), 0.3 1.36 (0.64, 2.90), 0.4 
Controlled BP Reference Reference Reference Reference 
All-cause mortality (N=349, 165 deaths) 
RH 1.74 (1.07, 2.82), 0.02 1.54 (0.94, 2.52), 0.08 1.16 (0.70, 1.94), 0.5 1.01 (0.60, 1.69), 0.9 
No RH 1.48 (0.91, 2.41), 0.1 1.20 (0.73, 1.97), 0.5 0.97 (0.58, 1.60), 0.9 0.90 (0.54, 1.50), 0.7 
Controlled BP Reference Reference Reference Reference 
Suppl. Table 7. Cox regression models for DN progression, incident CHD and stroke, and all-cause mortality according to the three groups: RH, no RH and 
controlled BP in individuals with type 1 diabetes when the BP threshold was set <130/80 mmHg 
Data are HR (95% CI) and p-values (Controlled BP reference group). *Time-varying effect of dependent variable. 
 
Model 1: Unadjusted 
Model 2: Adjusted for age/age group (age ≤35, 36-45, 46-55 and >55 years) 
Model 3: Model 2 + HbA1C, WHR, triglycerides, smoking and previous CHD and/or previous stroke 
Model 4: Model 3 + nephropathy status 
Model 5: Model 4 + eGFR/ renal stage (eGFR >90, 60-90 and <60 ml/min/1.73 m2) 
 
 
 
 
 
 
 
 
 Model 1 Model 2 Model 3 Model 4 Model 5 
DN progression (N=1103, 321 events) 
RH 
No RH 
 
(see Suppl. Fig. 7A)* 
3.47 (2.41, 5.00), <0.0001 
0.96 (0.68, 1.36), 0.8 
2.76 (1.85, 4.12), <0.0001 
0.93 (0.65, 1.34), 0.7 
2.17 (1.44, 3.26), 0.0002 
0.91 (0.63, 1.31), 0.6 
1.67 (1.11, 2.52), 0.01 
0.93 (0.65, 1.34), 0.7 
Controlled BP  Reference Reference Reference Reference 
Incident CHD (N=1015, 239 events) 
RH 2.39 (1.50, 3.80), 0.0002 1.92 (1.20, 3.07), 0.007  1.57 (0.96, 2.59), 0.07  1.43 (0.87, 2.36), 0.1 1.36 (0.82, 2.27), 0.2 
No RH 1.45 (0.95, 2.22), 0.08 1.25 (0.81, 1.91), 0.3 1.17 (0.75, 1.82), 0.5 1.22 (0.78, 1.89), 0.4 1.23 (0.79, 1.92), 0.3 
Controlled BP Reference Reference Reference Reference Reference 
Incident stroke (N=1066, 138 events) 
RH 3.16 (1.69, 5.91),  0.003 2.59 (1.38, 4.87), 0.003 2.38 (1.21, 4.68), 0.01 1.90 (0.95, 3.80), 0.07 1.52 (0.75, 3.09), 0.2 
No RH 1.59 (0.89, 2.86), 0.1 1.41 (0.78, 2.53 ), 0.2 1.47 (0.80, 2.72), 0.2 1.53 (0.83, 2.83), 0.2 1.57 (0.85, 2.90), 0.1 
Controlled BP Reference Reference Reference Reference Reference 
All-cause mortality (N=1103, 302 deaths) 
RH  2.96 (1.96, 4,46), <0.0001 2.46 (1.62, 3.72), <0.0001 1.72 (1.11, 2.66), 0.01 1.32 (0.85, 2.06), 0.2 1.23 (0.79, 1.93), 0.3 
No RH  1.41 (0.96, 2.08), 0.08 1.25 (0.85, 1.84), 0.3 1.16 (0.79, 1.73), 0.4 1.12 (0.76, 1.66), 0.6 1.13 (0.77, 1.68), 0.5 
Controlled BP Reference Reference Reference Reference Reference 
Suppl. Table 8. List of physicians and nurses at each of the FinnDiane centers participating in patient recruitment and 
characterization 
 
The Finnish Diabetic Nephropathy Study Centers 
Anjalankoski Health Center  S.Koivula, T.Uggeldahl 
Central Finland Central Hospital, Jyväskylä  T.Forslund, A.Halonen, A.Koistinen, P.Koskiaho, M.Laukkanen, J.Saltevo, M.Tiihonen                  
Central Hospital of Åland Islands, Mariehamn  M.Forsen, H.Granlund, A.-C.Jonsson, B.Nyroos 
Central Hospital of Kanta-Häme, Hämeenlinna  P.Kinnunen, A.Orvola, T.Salonen, A.Vähänen 
Central Hospital of Kymenlaakso, Kotka  R.Paldanius, M.Riihelä, L.Ryysy 
Central Hospital of Länsi-Pohja, Kemi H.Laukkanen, P.Nyländen, A.Sademies 
Central Ostrobothnian Hospital District, Kokkola  S.Anderson, B.Asplund, U.Byskata, P.Liedes, M.Kuusela, T.Virkkala 
City of Espoo Health Center: 
Espoonlahti    A.Nikkola, E.Ritola 
Tapiola    M.Niska, H.Saarinen 
Samaria    E.Oukko-Ruponen, T.Virtanen 
Viherlaakso    A.Lyytinen 
City of Helsinki Health Center: 
Puistola    H.Kari, T.Simonen 
Suutarila    A.Kaprio, J.Kärkkäinen, B.Rantaeskola 
Töölö    P.Kääriäinen, J.Haaga, A-L.Pietiläinen 
City of Hyvinkää Health Center   S.Klemetti, T.Nyandoto, E.Rontu, S.Satuli-Autere 
City of Vantaa Health Center: 
Korso    R.Toivonen, H.Virtanen 
Länsimäki    R.Ahonen, M.Ivaska-Suomela, A.Jauhiainen 
Martinlaakso    M.Laine, T.Pellonpää, R.Puranen 
Myyrmäki    A.Airas, J.Laakso, K.Rautavaara 
Rekola    M.Erola, E.Jatkola 
Tikkurila    R.Lönnblad, A.Malm, J.Mäkelä, E.Rautamo 
Heinola Health Center   P.Hentunen, J.Lagerstam 
Helsinki University Central Hospital, Department of      M.Feodoroff, D.Gordin, O.Heikkilä, K.Hietala, J.Fagerudd, M.Korolainen, L.Kyllönen,      
Medicine, Division of Nephrology                                  J.Kytö, S.Lindh, K.Pettersson-Fernholm, M.Rosengård-Bärlund, A.Sandelin, L.Thorn, 
                                                                                       J.Tuomikangas, T.Vesisenaho, J.Wadén  
Herttoniemi Hospital, Helsinki   V.Sipilä 
Hospital of Lounais-Häme, Forssa   T.Kalliomäki, J.Koskelainen, R.Nikkanen, N.Savolainen, H.Sulonen, E.Valtonen 
Hyvinkää Hospital  L. Norvio, A.Hämäläinen 
Iisalmi Hospital    E.Toivanen 
Jokilaakso Hospital, Jämsä   A.Parta, I.Pirttiniemi 
Jorvi Hospital, Helsinki University Central Hospital       S.Aranko, S.Ervasti, R.Kauppinen-Mäkelin, A.Kuusisto, T.Leppälä, K.Nikkilä, L.Pekkonen 
Jyväskylä Health Center, Kyllö   K.Nuorva, M.Tiihonen 
Kainuu Central Hospital, Kajaani   S.Jokelainen, K.Kananen, M.Karjalainen, P.Kemppainen, A-M.Mankinen, A.Reponen 
   M.Sankari    
Kerava Health Center   H.Stuckey, P.Suominen 
Kirkkonummi Health Center   A.Lappalainen, M.Liimatainen, J.Santaholma 
Kivelä Hospital, Helsinki   A.Aimolahti, E.Huovinen 
Koskela Hospital, Helsinki   V.Ilkka, M.Lehtimäki 
Kotka Health Center   E.Pälikkö-Kontinen, A.Vanhanen 
Kouvola Health Center   E.Koskinen, T.Siitonen 
Kuopio University Hospital                                            E.Huttunen, R.Ikäheimo, P.Karhapää, P.Kekäläinen, M.Laakso, T.Lakka, E.Lampainen,  
                             L.Moilanen, S. Tanskanen, L.Niskanen, U.Tuovinen, I.Vauhkonen, E.Voutilainen 
Kuusamo Health Center   T.Kääriäinen, E.Isopoussu 
Kuusankoski Hospital   E.Kilkki, I.Koskinen, L.Riihelä 
Laakso Hospital, Helsinki   T.Meriläinen, P.Poukka, R.Savolainen, N.Uhlenius 
Lahti City Hospital   A.Mäkelä, M.Tanner 
Lapland Central Hospital, Rovaniemi  L.Hyvärinen, K.Lampela, S.Pöykkö, T.Rompasaari, S.Severinkangas, T.Tulokas 
Lappeenranta Health Center   P. Erola, L.Härkönen, P.Linkola, T.Pekkanen, I.Pulli, E.Repo  
Lohja Hospital    T.Granlund, K.Hietanen, M.Porrassalmi, M.Saari, T.Salonen, M.Tiikkainen,  
Länsi-Uusimaa Hospital, Tammisaari  I.-M.Jousmaa, J.Rinne 
Loimaa Health Center   A.Mäkelä, P.Eloranta 
Malmi Hospital, Helsinki   H.Lanki, S.Moilanen, M.Tilly-Kiesi 
Mikkeli Central Hospital   A.Gynther, R.Manninen, P.Nironen, M.Salminen, T.Vänttinen 
Mänttä Regional Hospital   I.Pirttiniemi, A-M.Hänninen 
North Karelian Hospital, Joensuu   U-M.Henttula, P.Kekäläinen, M.Pietarinen, A.Rissanen, M.Voutilainen 
Nurmijärvi Health Center   A.Burgos, K.Urtamo 
Oulaskangas Hospital, Oulainen   E.Jokelainen, P-L.Jylkkä, E.Kaarlela, J.Vuolaspuro 
Oulu Health Center   L.Hiltunen, R.Häkkinen, S.Keinänen-Kiukaanniemi 
Oulu University Hospital   R.Ikäheimo 
Päijät-Häme Central Hospital   H.Haapamäki, A.Helanterä, S.Hämäläinen, V.Ilvesmäki, H.Miettinen 
Palokka Health Center   P.Sopanen, L.Welling 
Pieksämäki Hospital   V.Sevtsenko, M.Tamminen 
Pietarsaari Hospital   M-L.Holmbäck, B.Isomaa, L.Sarelin 
Pori City Hospital   P.Ahonen, P.Merisalo, E.Muurinen, K.Sävelä 
Porvoo Hospital    M.Kallio, B.Rask, S.Rämö 
Raahe Hospital    A.Holma, M.Honkala, A.Tuomivaara, R.Vainionpää 
Rauma Hospital    K.Laine, K.Saarinen, T.Salminen 
Riihimäki Hospital   P.Aalto, E.Immonen, L.Juurinen 
Salo Hospital    A.Alanko, J.Lapinleimu, P.Rautio, M.Virtanen 
Satakunta Central Hospital, Pori   M.Asola, M.Juhola, P.Kunelius, M.-L.Lahdenmäki, P.Pääkkönen, M.Rautavirta 
Savonlinna Central Hospital                                           T.Pulli, P.Sallinen, M.Taskinen, E.Tolvanen, T.Tuominen, H.Valtonen, A.Vartia, S-L.Viitanen 
Seinäjoki Central Hospital                                              O.Antila, E.Korpi-Hyövälti, T.Latvala, E.Leijala, T.Leikkari, M.Punkari, N.Rantamäki,  
                                                                                       H.Vähävuori  
South Karelia Central Hospital, Lappeenranta  T.Ensala, E.Hussi, R.Härkönen, U.Nyholm, J.Toivanen 
Tampere Health Center                                                  A.Vaden, P.Alarotu, E.Kujansuu, H.Kirkkopelto-Jokinen, M.Helin, S.Gummerus, L.Calonius,    
                                                                                       T.Niskanen, T.Kaitala, T.Vatanen 
Tampere University Hospital  P. Hannula, I.Ala-Houhala, R.Kannisto, T.Kuningas, P.Lampinen, M.Määttä, 
   H.Oksala, T.Oksanen, A.Putila, H.Saha, K.Salonen, H.Tauriainen, S.Tulokas 
Tiirismaa Health Center, Hollola   T.Kivelä, L.Petlin, L.Savolainen 
Turku Health Center   A.Artukka, I.Hämäläinen, L.Lehtinen, E.Pyysalo, H.Virtamo, M.Viinikkala, M.Vähätalo 
Turku University Central Hospital   K.Breitholz, R.Eskola, K.Metsärinne, U.Pietilä, P.Saarinen, R.Tuominen, S.Äyräpää 
Vaajakoski Health Center   K.Mäkinen, P.Sopanen 
Valkeakoski Regional Hospital   S.Ojanen, E.Valtonen, H.Ylönen, M.Rautiainen,T.Immonen 
Vammala Regional Hospital   I.Isomäki, R.Kroneld, L.Mustaniemi, M.Tapiolinna-Mäkelä 
Vaasa Central Hospital   S.Bergkulla, U.Hautamäki, V-A.Myllyniemi, I.Rusk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary figures 
 
To test time-varying effects 
The time-dependent effects of the variables were tested by using the Schoenfeld residuals against the follow-
up time (cox.zph, Survival package in R) (30). The assumption is that the hazard rate of an individual is 
constant over time. When the proportional hazards assumption of the Cox model is not fulfilled, the effect of 
the covariate is time-varying. When a time-varying effect emerged in an independent variable, we stratified 
the variable. When the effect occurred in the dependent variable, we visually inspected how the covariate on 
DN progression (or other outcomes) varied over time (29). Following the method of Zhang et al. (29), we 
stratified the follow-up time into distinct intervals, so that the proportional hazard assumption was fulfilled 
for each time interval.   
 
1. Risk of DN progression in all individuals (see Table 1 in the main text) 
 
Fig. 1A. In the Model 1 (unadjusted) time-varying effect of RH group 2 (no RH) 
 
  By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 5.0 ≥ 5.0 
RH 3.49 (2.28, 5.32), <0.0001 3.23 (2.02, 5.15), <0.0001 
No RH 0.71 (0.46, 1.11), 0.1 1.26 (0.83, 1.90), 0.3 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group).  
The risk of DN progression was higher in individuals with RH during the both time periods, while the risk did not 
differed in those with no RH compared with those who had controlled BP. 
 
Fig. 1B. In the Model 2 (adjusted for age and sex) time-varying effect of RH group 2 (no RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
Follow-up (years) < 5.5 ≥ 5.5 
RH 3.63 (2.39, 5.50), <0.0001      4.22 (2.52, 7.04), <0.0001 
No RH 0.75 (0.49, 1.14), 0.1 1.53 (0.98, 2.38), 0.3 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group).  
The risk of DN progression was higher in individuals with RH during the both time periods, while the risk did not 
differed in those with no RH compared with those who had controlled BP. 
 
2. The risk of DN progression in women (see Suppl. Table 2) 
 
Fig. 2A. In the Model 1 (unadjusted) time-varying effect of RH group 2 (no RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 4.4 ≥ 4.4 
RH 3.19 (1.71, 5.94), 0.0003 4.22 (2.13, 8.38), <0.0001 
No RH 0.39 (0.19, 0.79), 0.009 1.43 (0.82, 2.50), 0.2 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
The risk of DN progression in those with no RH was even lower during the first time period (< 4.4 years), compared 
with those who had controlled BP, but no differences were observed afterwards (≥ 4.4 years).  
 
Fig. 2B. In the Model 2 (adjusted for age) time-varying effect of RH group 2 (no RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 4.0 ≥ 4.0 
RH 3.67 (1.90, 7.11), 0.0001 5.29 (2.71, 10.34), <0.0001 
No RH 0.34 (0.15, 0.75), 0.007 1.63 (0.94, 2.81), 0.08 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
The risk of DN progression in those with no RH was even lower during the first time period (< 4.0 years), compared 
with those who had controlled BP, but no differences were observed afterwards (≥ 4.0 years).  
 
 
Fig. 2C. In the Model 3 (adjusted for age, HBA1c, WHR, triglycerides, smoking, previous CHD, previous stroke) 
time-varying effect of RH group 2 (no RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 4.0 ≥ 4.0 
RH 3.14 (1.48, 6.69), 0.003 4.42 (2.15, 9.11), <0.0001 
No RH 0.34 (0.14, 0.78), 0.01 1.41 (0.80, 2.49), 0.2 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
The risk of DN progression in those with no RH was even lower during the first time period (< 4.0 years), compared 
with those who had controlled BP, but no differences were observed afterwards (≥ 4.0 years).  
 
Fig. 2D. In the Model 3 (adjusted for age, HBA1c, WHR, triglycerides, smoking, previous CHD, previous stroke, 
nephropathy status) time-varying effect of RH group 2 (no RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 4.2 ≥ 4.2 
RH 2.47 (1.18, 5.17), 0.01 3.12 (1.49, 6.54), 0.003 
No RH 0.32 (0.14, 0.75), 0.009 1.37 (0.77, 2.44), 0.3 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
The risk of DN progression in those with no RH was even lower during the first time period (< 4.2 years), compared 
with those who had controlled BP, but no differences were observed afterwards (≥ 4.2 years).  
 
 
Fig. 2E. In the Model 3 (adjusted for age, HBA1c, WHR, triglycerides, smoking, previous CHD, previous stroke, 
nephropathy status, renal stage) time-varying effect of RH group 2 (no RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 4.2 ≥ 4.2 
RH 1.78 (0.85, 3.72), 0.1 2.14 (1.01, 4.52), 0.05 
No RH 0.33 (0.14, 0.79), 0.01 1.31 (0.73, 2.36), 0.3 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
The risk of DN progression in those with no RH was even lower during the first time period (< 4.2 years), compared 
with those who had controlled BP, but no differences were observed afterwards (≥ 4.2 years).  
 
3. The risk of CHD in women (see Suppl. Table 2) 
 
Fig. 3A. In the Model 1 time-varying effect (unadjusted) of RH group 1 (RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 6.2 ≥ 6.2 
RH 5.85 (2.06, 16.60), 0.0009 2.71 (1.23, 5.97), 0.01 
No RH 2.65 (1.01, 6.95), 0.05 1.96 (1.07, 3.61), 0.03 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group).  
The risk of CHD was higher in individuals with RH during the both time periods (especially during <6.2 years follow-
up), and the risk was also higher in those with no RH, compared with those who had controlled BP. 
 
 
 
 
 
Fig. 3B. In the Model 2 (adjusted for age) time-varying effect of RH group 1 (RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 6.2 ≥ 6.2 
RH 3.56 (1.24, 10.26), 0.02 1.76 (0.78, 3.93), 0.2 
No RH 1.66 (0.62, 4.42), 0.3 1.38 (0.74, 2.58), 0.3 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group).  
The risk of CHD was higher in individuals with RH only during the first time period (<6.2 years), but not afterwards, 
while the risk did not differed in those with no RH, compared with those who had controlled BP. 
 
Fig. 3C. In the Model 3 (adjusted for age, HBA1c, WHR, triglycerides, smoking, previous stroke) time-varying 
effect of RH group 1 (RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 6.5 ≥ 6.5  
RH 2.90 (0.99, 8.51), 0.05  1.65 (0.71, 3.80), 0.2  
No RH 1.46 (0.54, 3.93), 0.4 1.38 (0.72, 2.64), 0.3  
Controlled BP Reference Reference  
Data are HR (95% CI) and p-values (Controlled BP reference group).  
The CHD risk did not differed in those with RH or no RH, compared with those who had controlled BP. 
 
 
 
 
 
 
 
Fig. 3D. In the Model 3 (adjusted for age, HBA1c, WHR, triglycerides, smoking, previous stroke, nephropathy 
status) time-varying effect of RH group 1 (RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 9.0 ≥ 9.0 
RH 2.65 (1.05, 6.65), 0.04 1.15 (0.43, 3.06), 0.8 
No RH 1.45 (0.62, 3.38), 0.4 1.39 (0.69, 2.82), 0.3 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group).  
After full adjustment the CHD risk was higher in women with RH during the first time period (< 9 years), but not 
afterwards, while the risk did not differed in those with no RH, compared with those who had controlled BP. 
 
Fig. 3E. In the Model 3 (adjusted for age, HBA1c, WHR, triglycerides, smoking, previous stroke, nephropathy 
status, renal stage) time-varying effect of RH group 1 (RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 9.0 ≥ 9.0 
RH 2.47 (0.98, 6.23), 0.05 1.09 (0.41, 2.91), 0.8 
No RH 1.45 (0.62, 3.37), 0.4 1.40 (0.69, 2.84), 0.3 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group).  
The CHD risk did not differed in those with RH or no RH, compared with those who had controlled BP. 
 
 
4. Risk of DN progression in those with normal AER and microalbuminuria (see Suppl. Table 3) 
 
 
 
 
Fig. 4A. In the Model 1 (unadjusted) time-varying effect of RH group 2 (no RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 5.4 ≥ 5.4 
RH 0.81(0.27, 2.41), 0.7 1.08 (0.30, 3.93), 0.9 
No RH 0.63 (0.33, 1.18), 0.1 1.55 (0.77, 3.11), 0.2 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
The DN progression risk did not differed in those with RH or no RH, compared with those who had controlled BP. 
 
Fig. 4B. In the Model 2 (adjusted for age and sex) time-varying effect of RH group 2 (no RH)  
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 4.2 4.2 – 7.5 > 7.5 
RH 0.69 (0.20, 2.39), 0.5      0.94 (0.20, 4.55), 0.9 1.53 (0.30, 7.87), 0.6 
No RH 0.43 (0.21, 0.89), 0.02      1.40 (0.60, 3.25), 0.4 1.94 (0.74, 5.09), 0.2 
Controlled BP Reference Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
During the first 4.2 years the risk of DN progression was slightly lower in those with no RH, while no differences 
were observed in those with RH, compared with those who had controlled BP. 
 
 
5. Risk of CHD in individuals with macroalbuminuria (see Suppl. Table 4.) 
 
 
 
 
 
 
Fig. 5A. In the Model 2 (adjusted for age and sex) time-varying effect of RH group 1 (RH)  
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 4.0 4.0 – 10.0 > 10.0 
RH 1.81 (0.59, 5.53), 0.3      2.60 (0.87, 7.77), 0.09 0.89 (0.42, 1.87), 0.8 
No RH 1.03 (0.34, 3.12), 1.0      1.60 (0.54, 4.70), 0.4 1.12 (0.59, 2.14), 0.7 
Controlled BP Reference Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
The CHD risk did not differed in those with RH or no RH, compared with those who had controlled BP. 
 
 
6. Risk of DN progression in those with eGFR ≥60 ml/min/1.73 m2 (see Suppl. Table 5.) 
 
Fig. 6A. In the Model 1 (unadjusted) time-varying effect of RH group 1 (RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 5.3 5.3 – 10.0 > 10.0 
RH 0.20 (0.03, 1.56), 0.1 3.54 (1.19, 10.53), 0.02 1.11 (0.23, 5.34), 0.9 
No RH 0.70 (0.36, 1.35), 0.3 1.91(0.79, 4.62), 0.1 1.31 (0.56, 3.08), 0.5 
Controlled BP Reference Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group).  
In individuals with eGFR ≥60 ml/min/1.73 m2 the risk of DN progression was higher in those with RH during the 
time-period of 5.3–10.0 years, but no differences were observed between the groups before and after that time period.  
 
 
 
 
 
 
 
 
Fig. 6B. In the Model 2 (adjusted for age and sex) time-varying effect of RH group 1 (RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 5.3 5.3 – 10.0 > 10.0 
RH 1.00 (0.33, 3.08), 1.0 1.09 (0.22, 5.31), 0.9 1.08 (0.12, 9.74), 0.9 
No RH 0.71 (0.37, 1.36), 0.3 1.38 (0.58, 3.24), 0.5 1.65 (0.54, 5.00), 0.4 
Controlled BP Reference Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group). 
The DN progression risk did not differed in those with RH or no RH, compared with those who had controlled BP 
during the follow-up. 
 
Fig. 6C. In the Model 3 (adjusted for age, sex, HBA1c, waist, triglycerides, smoking, previous CHD and stroke) 
time-varying effect of RH group 1 (RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 5.5 5.5 – 10.0 > 10.0 
RH 0.19 (0.02, 1.47), 0.1 2.49 (0.78, 7.91), 0.1 0.89 (0.18, 4.38), 0.9 
No RH 0.67 (0.34, 1.32), 0.2 1.71(0.70, 4.17), 0.2 0.98 (0.41, 2.37), 1.0 
Controlled BP Reference Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group).  
The DN progression risk did not differed in those with RH or no RH, compared with those who had controlled BP 
during the follow-up. 
 
 
 
 
 
 
Fig. 6D. In the Model 4 (adjusted for age, sex, HBA1c, waist, triglycerides, smoking, nephropathy status, 
previous CHD and stroke) time-varying effect of RH group 1 (RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 5.5 5.5 – 10.0 > 10.0 
RH 0.19 (0.02, 1.52), 0.1 2.54 (0.80, 8.10), 0.1 0.91 (0.18, 4.46), 0.9 
No RH 0.66 (0.34, 1.32), 0.2 1.71 (0.70, 4.16), 0.2 0.98 (0.40, 2.36), 1.0 
Controlled BP Reference Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group).  
The DN progression risk did not differed in those with RH or no RH, compared with those who had controlled BP 
during the follow-up. 
 
 
7. The Risk of DN progression in all individuals with the BP threshold of < 130/80 mmHg (Suppl. Table 7.) 
 
Fig. 7A. In the Model 1 (unadjusted) time-varying effect of RH group 1 (RH) 
 
By splitting the follow-up, the proportional hazard assumption was fulfilled in each time-interval. 
 
Follow-up (years) < 5.1 ≥ 5.1 
RH 3.44 (2.09, 5.65), <0.0001 2.91 (1.73, 4.89), <0.0001 
No RH 0.75 (0.46, 1.24), 0.3 1.11 (0.69, 1.77), 0.7 
Controlled BP Reference Reference 
Data are HR (95% CI) and p-values (Controlled BP reference group).  
The risk of DN progression was higher in individuals with RH during the both time periods, while the risk did not 
differed in those with no RH compared with those who had controlled BP. 
 
